combination of funding and commercial expertise offers an orthogonal value add to academic excellence.
At a time when the industry is reducing its own footprint (and personnel) at an alarming rate, it falls to the university to provide a compelling case for channeling resources into an academic proposition.
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Conclusions
Fostering industry partnerships to drive academic entrepreneurship in the current, extremely competitive funding environment requires a scientifically driven approach. Research universities are increasingly looking to alternative bodies for funding sources and, as a result, the pharmaceutical industry has become inundated with investment opportunities. To differentiate their venture pitch, universities must build a strong business case to communicate where a discovery fits in the scientific portfolio of a potential industry partner. CVC alone will not address the academic valley of death, but industry's First Rounders Podcast:
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